Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group

Joann L. Ater, Caihong Xia, Claire M. Mazewski, Timothy N. Booth, David R. Freyer, Roger J. Packer, Richard Sposto, Gilbert Vezina, Ian F. Pollack

Research output: Contribution to journalArticle

27 Scopus citations


BACKGROUND: To evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV). METHODS: Non-NF1 patients were randomized to CV or thioguanine, procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine in COG A9952. NF1 patients were assigned to CV only. NF1 patients and non-NF1 patients who were treated with CV were compared with respect to baseline characteristics, toxicity, tumor responses, EFS, and OS. RESULTS: A total of 127 eligible patients with NF1 were nonrandomly assigned to CV: 42 NF1 patients (33%) had events, and 6 (4.7%) died. The 5-year EFS rate was 69%±4% for the CV-NF1 group and 39%±4% for the CV-non-NF1 group (P

Original languageEnglish (US)
StateAccepted/In press - 2016



  • Carboplatin
  • Childhood low-grade glioma
  • Neurofibromatosis 1
  • Pilocytic astrocytoma
  • Vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this